KR102090551B1 - 소수성 단백질의 새로운 방출 시스템 - Google Patents

소수성 단백질의 새로운 방출 시스템 Download PDF

Info

Publication number
KR102090551B1
KR102090551B1 KR1020147033477A KR20147033477A KR102090551B1 KR 102090551 B1 KR102090551 B1 KR 102090551B1 KR 1020147033477 A KR1020147033477 A KR 1020147033477A KR 20147033477 A KR20147033477 A KR 20147033477A KR 102090551 B1 KR102090551 B1 KR 102090551B1
Authority
KR
South Korea
Prior art keywords
protein
amide
timp
treatment
biologically active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020147033477A
Other languages
English (en)
Korean (ko)
Other versions
KR20150016951A (ko
Inventor
모니카 캄피시
크리스티안 구아리스
다비드 레니에르
Original Assignee
피디아 파마슈티치 에스.피.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 피디아 파마슈티치 에스.피.에이. filed Critical 피디아 파마슈티치 에스.피.에이.
Publication of KR20150016951A publication Critical patent/KR20150016951A/ko
Application granted granted Critical
Publication of KR102090551B1 publication Critical patent/KR102090551B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2235—Secretins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L89/00—Compositions of proteins; Compositions of derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
KR1020147033477A 2012-05-31 2013-05-30 소수성 단백질의 새로운 방출 시스템 Active KR102090551B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT000173A ITPD20120173A1 (it) 2012-05-31 2012-05-31 "nuovo sistema di rilascio di proteine idrofobiche"
ITPD2012A000173 2012-05-31
PCT/IB2013/054477 WO2013179258A1 (en) 2012-05-31 2013-05-30 New release system of hydrophobic proteins

Publications (2)

Publication Number Publication Date
KR20150016951A KR20150016951A (ko) 2015-02-13
KR102090551B1 true KR102090551B1 (ko) 2020-03-19

Family

ID=46321311

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147033477A Active KR102090551B1 (ko) 2012-05-31 2013-05-30 소수성 단백질의 새로운 방출 시스템

Country Status (13)

Country Link
US (1) US9731019B2 (enExample)
EP (1) EP2854830B1 (enExample)
JP (1) JP6247687B2 (enExample)
KR (1) KR102090551B1 (enExample)
CN (1) CN104349788B (enExample)
CA (1) CA2874958C (enExample)
EA (1) EA031390B1 (enExample)
ES (1) ES2885764T3 (enExample)
IN (1) IN2014KN02739A (enExample)
IT (1) ITPD20120173A1 (enExample)
MX (1) MX357799B (enExample)
PT (1) PT2854830T (enExample)
WO (1) WO2013179258A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201900003887A1 (it) 2019-03-18 2020-09-18 Fidia Farm Spa Sistemi di stabilizzazione e di rilascio controllato di farmaci instabili alla sterilizzazione
IT201900009933A1 (it) * 2019-06-24 2020-12-24 Fidia Farm Spa Composizioni farmaceutiche comprendenti derivati ammidici dell'acido ialuronico per uso nel trattamento di traumi ossei, in particolare in pazienti con problemi di osteopenia o osteoporosi
IT202300027378A1 (it) * 2023-12-20 2025-06-20 Fidia Farm Spa Sistema di rilascio per la somministrazione topica o intrarticolare di farmaci

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006092233A1 (en) 2005-03-02 2006-09-08 Fidia Farmaceutici S.P.A. Amide derivatives of hyaluronic acid in osteoarthrosis

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US495774A (en) 1893-04-18 Island
IT1229075B (it) 1985-04-05 1991-07-17 Fidia Farmaceutici Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico
FR2553099B1 (fr) 1983-10-11 1989-09-08 Fidia Spa Fractions d'acide hyaluronique ayant une activite pharmaceutique, procedes pour leur preparation et compositions pharmaceutiques les contenant
US4582865A (en) 1984-12-06 1986-04-15 Biomatrix, Inc. Cross-linked gels of hyaluronic acid and products containing such gels
US4713448A (en) 1985-03-12 1987-12-15 Biomatrix, Inc. Chemically modified hyaluronic acid preparation and method of recovery thereof from animal tissues
US4851521A (en) 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
IT1219587B (it) 1988-05-13 1990-05-18 Fidia Farmaceutici Polisaccaridi carbossiilici autoreticolati
CA1340994C (en) 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
US5827937A (en) 1995-07-17 1998-10-27 Q Med Ab Polysaccharide gel composition
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
ITPD980169A1 (it) * 1998-07-06 2000-01-06 Fidia Advanced Biopolymers Srl Ammidi dell'acido ialuronico e dei suoi derivati e processo per la loro preparazione.
IT1306679B1 (it) 1999-06-29 2001-10-02 Fidia Advanced Biopolymers Srl Uso dei derivati dell'acido ialuronico per la preparazione dicomposizoni farmaceutiche e biomateriali per la prevenzione della
US6645485B2 (en) 2000-05-10 2003-11-11 Allan R. Dunn Method of treating inflammation in the joints of a body
US20080220053A1 (en) * 2004-12-14 2008-09-11 Fidia Advanced Biopolymers S.R.L. Process for the Preparation of Two and Three Dimensional Polymer Scaffolds
MY139088A (en) 2005-02-21 2009-08-28 Lg Life Sciences Ltd Sustained release composition of protein drug
ITPD20050207A1 (it) * 2005-07-07 2007-01-08 Fidia Farmaceutici Nuove composizioni farmaceutiche contenenti acido ialuronico e collagenas nel trattamento topico di ferite, ustioni ed ulcere
IT1402385B1 (it) 2010-09-09 2013-09-04 Fidia Farmaceutici Processo per la produzione di acido ialuronico in escherichia coli o bacillus subtilis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006092233A1 (en) 2005-03-02 2006-09-08 Fidia Farmaceutici S.P.A. Amide derivatives of hyaluronic acid in osteoarthrosis

Also Published As

Publication number Publication date
MX2014014536A (es) 2015-02-24
JP2015518042A (ja) 2015-06-25
EP2854830A1 (en) 2015-04-08
US20150290326A1 (en) 2015-10-15
US9731019B2 (en) 2017-08-15
KR20150016951A (ko) 2015-02-13
CN104349788B (zh) 2017-07-28
CA2874958C (en) 2023-02-14
EA031390B1 (ru) 2018-12-28
PT2854830T (pt) 2021-09-02
ES2885764T3 (es) 2021-12-15
IN2014KN02739A (enExample) 2015-05-08
CN104349788A (zh) 2015-02-11
EA201491991A1 (ru) 2015-03-31
MX357799B (es) 2018-07-25
CA2874958A1 (en) 2013-12-05
HK1206993A1 (en) 2016-01-22
JP6247687B2 (ja) 2017-12-13
ITPD20120173A1 (it) 2013-12-01
WO2013179258A1 (en) 2013-12-05
EP2854830B1 (en) 2021-06-30

Similar Documents

Publication Publication Date Title
Qiu et al. A hydrogel prepared by in situ cross-linking of a thiol-containing poly (ethylene glycol)-based copolymer: a new biomaterial for protein drug delivery
KR100577041B1 (ko) 서방성제형
US9561260B2 (en) Compositions for treating joints comprising bone morphogenetic protein and hyaluronic acid
EP2086567B1 (en) Sustained release formulations comprising very low molecular weight polymers
US8524662B2 (en) Compositions and methods for treating joints
CN1230108A (zh) 用于持续释放蛋白质药物的温敏凝胶
Motokawa et al. Selectively crosslinked hyaluronic acid hydrogels for sustained release formulation of erythropoietin
CN108697717A (zh) 治疗关节的组合物
Liu et al. Improving the protective effects of aFGF for peripheral nerve injury repair using sulfated chitooligosaccharides
JP2015057384A (ja) 薬学的使用のための新規のニュールツリン複合体
Wang et al. Characterization, stability, and formulations of basic fibroblast growth factor
KR102090551B1 (ko) 소수성 단백질의 새로운 방출 시스템
EP3086803B1 (en) Fgf-18 formulation in xyloglucan gels
US20140162948A1 (en) Formulation for increasing bioavailability of neurturin
WO2017168428A9 (en) Treatments utilizing a polymer-protein conjugate
US20110287068A1 (en) Fibrin and fibrinogen matrices and uses of same
US11951176B2 (en) Stabilization of glucagon by trehalose glycopolymer nanogels
HK1206993B (en) New release system of hydrophobic proteins
KR20140015264A (ko) 서방성 의약 조성물
RU2664192C1 (ru) Рекомбинантный ген, кодирующий белок hbd-epo, рекомбинантная плазмидная днк pl610, способ получения рекомбинантного белка hbd-epo, рекомбинантный белок hbd-epo, композиция для специфической индукции регенерации костной ткани, способ специфической индукции регенерации костной ткани

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 6